GENTA INC DE/ Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-08-02: Form 8-K; Period of report 2012-08-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2012-07-30: Form 8-K; Period of report 2012-07-30; Description 8.01 Other Events; Details 8.01.
- 2012-07-27: Form 8-K; Period of report 2012-07-24; Description 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review; Details 4.02.
- 2012-07-26: Form 8-K; Period of report 2012-07-26; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-08-02 | 8-K | 2012-08-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Upon the Filing, the officers will be terminated, and the directors will resign effective immediately upon the Filing. 8.01 On August 2, 2012, Genta Incorporated (the “Company), intends to file a voluntary petition for relief under Chapter 7 of the United States Bankruptcy Code (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Filing”). | genta_8k-080212.htm |
| 2012-07-30 | 8-K | 2012-07-30 | 8.01 Other Events | 8.01 On July 30, 2012, Genta Incorporated (the “Company”) announced that it has received formal notice from the drug regulatory authority of the People’s Republic of China (SFDA) that the Company has received approval to start clinical trials with tesetaxel, its lead clinical compound, in China. | genta_8k-073012.htm |
| 2012-07-27 | 8-K | 2012-07-24 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 Genta Incorporated, (the “Company”) has determined that for the three-month period ended March 31, 2012, the Company’s financial statements included in Form 10-Q filed with the Securities and Exchange Commission on May 14, 2012 will need to be restated for the item described below and therefore should not be relied upon. | genta_8k-072412.htm |
| 2012-07-26 | 8-K | 2012-07-26 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Genta Incorporated, (the Company), held its 2012 Annual Meeting of Stockholders on July 26, 2012. | genta_8k-072612.htm |
| 2012-06-18 | 8-K | 2012-06-18 | 8.01 Other Events | 8.01 On June 18, 2012, Genta Incorporated (the “Company”) announced that it has reached agreement with the U.S. Food and Drug Administration (“FDA”) under its Special Protocol Assessment (“SPA”) process for the Company’s proposed Phase 3 trial of oral tesetaxel as initial chemotherapy for women with metastatic breast cancer. | genta_8k-061812.htm |
| 2012-06-15 | 8-K | 2012-06-15 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 4,846,615,013. | genta_8k-061512.htm |
| 2012-06-15 | 8-K | 2012-06-13 | 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 3.02 Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 5.02 On June 13, 2012, the Compensation Committee of the Board of Directors of Genta Incorporated (the “Company”) approved the grant of restricted stock to the executive officers of the Company as follows: Raymond P. Warrell, Jr. M.D. (800,000,000 shares); Loretta M. Itri, M.D. (650,000,000 shares); and Gary Siegel (550,000,000 shares). | genta_8k-061312.htm |
| 2012-06-15 | 8-K | 2012-06-14 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | genta_8k-061412.htm |
| 2012-05-31 | 8-K | 2012-05-31 | 8.01 Other Events | 8.01 On May 31, 2012, Genta Incorporated announced that the first patient has been accrued to a new randomized trial of tesetaxel as initial chemotherapy for women with advanced or recurrent breast cancer. | genta_8k-053112.htm |
| 2012-05-25 | 8-K | 2012-05-25 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 2,657,552,779. | genta_8k-052512.htm |
| 2012-05-24 | 8-K | 2012-05-24 | 8.01 Other Events | 8.01 On May 24, 2012, Genta Incorporated announced results from results from the Company’s Phase 2, confirmatory, clinical trial of tesetaxel as 2nd-line treatment of patients with advanced gastric cancer. | genta_8k-052412.htm |
| 2012-05-22 | 8-K | 2012-05-22 | 8.01 Other Events | 8.01 On May 22, 2012, Genta Incorporated announced results from the Company’s Phase 2 clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer. | genta_8k-052212.htm |
| 2012-05-14 | 8-K | 2012-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2012, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter ended March 31, 2012. | genta_8k-051412.htm |
| 2012-05-08 | 8-K | 2012-05-08 | 8.01 Other Events | 8.01 On May 8, 2012, Genta Incorporated announced that the first patient has been accrued to a new randomized clinical trial of its lead compound, tesetaxel, in patients with advanced gastric cancer. | genta_8k-050812.htm |
| 2012-04-24 | 8-K | 2012-04-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 24, 2012, Genta Incorporated (the “Company”) announced that Daniel D. Von Hoff, M.D., resigned from the Board of Directors (the “Board”) of the Company. | genta_8k-042412.htm |
| 2012-04-20 | 8-K | 2012-04-20 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 2,212,407,559. | genta_8k-042012.htm |
| 2012-03-29 | 8-K | 2012-03-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | genta_8k-032812.htm |
| 2012-03-28 | 8-K | 2012-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2012, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter and year ended December 31, 2011. | genta_8k-032812.htm |
| 2012-03-28 | 8-K | 2012-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2012, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter and year ended December 31, 2011. | genta_8k-032812.htm |
| 2012-03-23 | 8-K | 2012-03-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 23, 2012, Genta Incorporated (the “Company”) announced that Ana I. Stancic resigned from the Board of Directors (the “Board”) of the Company and any Board committees, effective as of March 23, 2012. | genta20120323_8k.htm |
| 2012-03-16 | 8-K | 2012-03-16 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 2,026,398,605. | genta_8k-031612.htm |
| 2012-02-15 | 8-K | 2012-02-15 | 8.01 Other Events | 8.01 As previously disclosed, on September 2, 2011, Genta Incorporated, a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “September 2011 Purchase Agreement”) with certain accredited investors listed on the signature pages thereto, pursuant to which it agreed to issue up to $12.7 million of units (the “2011 Units”), each 2011 Unit consisting of (i) 12.00% senior secured convertible promissory notes due September 9, 2021, convertible into shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an initial conversion rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “G Notes”), (ii) 12.00% senior secured cash collateralized convertible promissory notes due September 9, 2021, convertible into shares of Common Stock at an initial conversion rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “H Notes”, together with the G Notes, the “September 2011 Notes”), (iii) senior secured convertible promissory note warrants to purchase an amount of G Notes equal to the G Notes purchased at the closing, at an exercise price of $1,000 per warrant (the “G Warrants”), which purchase price may be paid through a cashless “net exercise” feature, and (iv) senior secured cash collateralized convertible promissory note warrants to purchase an amount of G Notes equal to the H Notes purchased at closing, at an exercise price of $1,000 per warrant (the “H Warrants,” together with the G Warrants, the “September 2011 Debt Warrants”), which purchase price may also be paid through a cashless “net exercise” feature. | genta_8k-021412.htm |
| 2012-02-10 | 8-K | 2012-02-10 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 1,935,455,665. | genta_8k-021012.htm |
| 2012-01-27 | 8-K | 2012-01-27 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 1,733,460,585. | genta_8k-012712.htm |
| 2012-01-24 | 8-K | 2012-01-23 | 8.01 Other Events | 8.01 Earlier in 2011, Genta Incorporated, a Delaware corporation (the “Company”), submitted a request to the Financial Industry Regulatory Authority (“FINRA”) to process documentation related to a reverse stock split pursuant to Rule 10b-17 of the Securities Exchange Act of 1934, as amended (the “Reverse Split”). | genta_8k-012312.htm |
| 2012-01-19 | 8-K | 2012-01-18 | 8.01 Other Events | 8.01 On January 19, 2012, Genta Incorporated (“the Company”) announced results from the Company’s Phase 2b, confirmatory clinical trial of tesetaxel in patients with advanced gastric cancer. | genta_8k-01192012.htm |
| 2012-01-19 | 8-K | 2012-01-18 | 8.01 Other Events | 8.01 As previously disclosed, on September 2, 2011, Genta Incorporated, a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “September 2011 Purchase Agreement”) with certain accredited investors listed on the signature pages thereto, pursuant to which it agreed to issue up to $12.7 million of units (the “2011 Units”), each 2011 Unit consisting of (i) 12.00% senior secured convertible promissory notes due September 9, 2021, convertible into shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an initial conversion rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “G Notes”), (ii) 12.00% senior secured cash collateralized convertible promissory notes due September 9, 2021, convertible into shares of Common Stock at an initial conversion rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “H Notes”, together with the G Notes, the “September 2011 Notes”), (iii) senior secured convertible promissory note warrants to purchase an amount of G Notes equal to the G Notes purchased at the closing, at an exercise price of $1,000 per warrant (the “G Warrants”), which purchase price may be paid through a cashless “net exercise” feature, and (iv) senior secured cash collateralized convertible promissory note warrants to purchase an amount of G Notes equal to the H Notes purchased at closing, at an exercise price of $1,000 per warrant (the “H Warrants,” together with the G Warrants, the “September 2011 Debt Warrants”), which purchase price may also be paid through a cashless “net exercise” feature. | genta_8k-011812.htm |
| 2012-01-13 | 8-K | 2012-01-13 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 1,529,054,259. | genta_8k-011312.htm |